As of Nov 21, 2024, the NBIX stock has a PE ratio of 32.38. The calculation is based on the latest EPS of $3.86 and the stock price of $125 per share. A decrease of 18% has been observed in the PE ratio compared to its average of 39.5 of the last four quarters.
The mean historical PE ratio of Neurocrine Biosciences over the last seven years is 189.02. The current 32.38 P/E ratio is 83% lower than the historical average. Looking back at the last seven years, NBIX's PE ratio peaked in the Sep 2018 quarter at 1,229.5, with a price of $122.95 and an EPS of $0.1. The Sep 2021 quarter marked the lowest point at 20.11, with a price of $95.91 and an EPS of $4.77.
Maximum annual increase: 309.73% in 2021
Maximum annual decrease: -91.86% in 2020
Year | PE ratio | Change |
---|---|---|
2023 | 51.47 | -30.62% |
2022 | 74.19 | -17.24% |
2021 | 89.65 | 309.73% |
2020 | 21.88 | -91.86% |
2019 | 268.73 | -13.45% |
2018 | 310.48 | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
NBIX's current PE ratio is lower than its 3, 5 and 10-year averages.
In comparison to its peers LLY and ABBV, NBIX's PE ratio is lower, but it is higher than RPRX's. Neurocrine Biosciences's PE ratio is trading below the peer average of 45.92.
Stock name | PE ratio | Market cap |
---|---|---|
RPRX Royalty Pharma plc | 10.27 | $15.55B |
NBIX Neurocrine Biosciences Inc | 32.38 | $12.66B |
PFE Pfizer Inc | 33.07 | $142.41B |
ABBV AbbVie Inc | 59.63 | $303.47B |
LLY ELI LILLY & Co | 80.72 | $711.91B |
RGEN Repligen Corp | N/A | $7.94B |
PTN Palatin Technologies Inc | N/A | $18.35M |
ANIP Ani Pharmaceuticals Inc | N/A | $1.17B |
CASI CASI Pharmaceuticals Inc | N/A | $80.3M |
The price to earnings ratio for NBIX stock is 32.38 as of Nov 21, 2024.
Over the last 3 years, the average price to earnings ratio for NBIX stock is 135.77.
Over the last 5 years, the average price to earnings ratio for NBIX stock is 109.13.
The highest quarterly PE ratio in the last seven years has been 1,229.5 and it was in the Sep 2018 quarter.
NBIX's current price to earnings ratio is 83% below its 7-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Nov 21, 2024), Neurocrine Biosciences's share price is $125. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $3.86. Therefore, Neurocrine Biosciences's PE ratio for today is 32.38. PE RATIO(32.38) = STOCK PRICE($125) / TTM EPS($3.86)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.